AGENUS INC — Director's Dealing 2017

Apr 12, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGENUS INC (AGEN)
CIK: 0001098972
Period of Report: 2017-04-10

Reporting Person: ARMEN GARO H (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-10	Common Stock	P	70544	$3.3662	Acquired	1389021	Direct
2017-04-12	Common Stock	P	29456	$3.2949	Acquired	1418477	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4046	Indirect

Footnotes

F1: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.29 to $3.43. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares purchased at each price.

F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.255 to $3.33. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares purchased at each price.

F3: Dr. Armen is Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which as of the date of this report owns 4,046 shares of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Holdings and disclaims beneficial ownership to the extent of his pecuniary interest therein.